|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Background COVID-19 has brought into questioning the equitable distribution of resources. Solid Organ Transplants (SOT) are life-saving procedures. Rapid changes in the management of patients are occurring, with potential for inequity. Drawing on professionals across transplant specialities, we investigated resource distribution specifically for SOT to guide healthcare policies. A multidisciplinary team developed a survey. The survey included demographic questions to contextualise respondents, questions on resource allocation for SOT. Multiple strategies were used to distribute the survey internationally. Descriptive, uni-multivariate ordinal regressions analysis were performed. Open comments were analysed using qualitative methods.
Description: Question 1"Given the COVID-19 outbreak, should liver transplant activities be stopped?" with three possible answers (Completely, Selectively and Not at All)Measure: Management of Solid Organ Transplant during COVID-19 pandemic Time: 20/04/2020
Description: Question 2"I feel that the current policy to allocate most resources to COVID-19 meets the equity of access in healthcare for different diseases" with four possible alternative answers (strongly agree, partially agree, partially disagree and strongly disagree).Measure: Equity of resource distribution Time: 20/04/2020
Description: Scale (10 strongly agree- 0 strongly disagree).Measure: Equity rank of resource distribution Time: 20/04/2020
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports